Atortin-10mg
₨ 107.00
- Generic Name: Atorvastatin
- Brand Name: Atortin 10 mg
- Manufacturer: National Healthcare Pvt. Ltd.
- Indications: Hyperlipidemia (high cholesterol), prevention of cardiovascular events
- Dosage: 10 mg once daily, as prescribed by a healthcare professional
- Common Side Effects: Headache, muscle pain, nausea, abdominal pain
-
Indications:
- Atortin 10 mg is prescribed for the treatment of hyperlipidemia, aiming to lower elevated cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol, and triglycerides in the blood.
- It is also utilized to reduce the risk of cardiovascular events such as heart attacks and strokes.
-
Dosage and Administration:
- The typical dosage of Atortin 10 mg is one tablet taken orally once daily, with or without food.
- The exact dosage and duration of treatment should be determined by a healthcare provider based on individual patient needs and response to therapy.
-
Mechanism of Action:
- Atortin 10 mg functions by inhibiting the enzyme HMG-CoA reductase in the liver. This inhibition decreases the production of cholesterol, leading to lower levels of LDL cholesterol and triglycerides in the blood, thereby reducing the risk of atherosclerosis and associated cardiovascular events.
-
Common Side Effects:
- Some individuals may experience side effects such as headache, muscle pain, nausea, and abdominal discomfort. If any adverse reactions occur, it is important to consult a healthcare professional promptly.
-
Precautions:
- Before initiating treatment with Atortin 10 mg, inform your healthcare provider of any existing medical conditions, especially liver disease, kidney disease, or a history of muscle disorders.
- Additionally, disclose all medications and supplements you are currently taking to avoid potential drug interactions.
-
Monitoring:
- Regular monitoring of cholesterol levels and liver function tests is recommended during treatment with Atortin 10 mg to assess efficacy and detect any potential side effects.







Reviews
There are no reviews yet.